<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530995</url>
  </required_header>
  <id_info>
    <org_study_id>KD025-107</org_study_id>
    <nct_id>NCT03530995</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers</brief_title>
  <official_title>A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, 2-part, non-randomized, open-label study of the drug-drug&#xD;
      interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and&#xD;
      omeprazole in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1:&#xD;
&#xD;
      The primary objective of Part 1 of this study is to determine the effect of itraconazole,&#xD;
      rifampicin, and rabeprazole on the pharmacokinetics of once daily (QD) orally administered&#xD;
      belumosudil in healthy male subjects. Part 1 consists of 4 periods.&#xD;
&#xD;
      In each study period, subjects will receive a single dose of belumosudil, in the fed state.&#xD;
      Additionally, in order to assess the effects of inhibition and induction of CYP3A4 and the&#xD;
      elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of&#xD;
      perpetrator drugs in Periods 2 to 4; a strong CYP3A4 inhibitor, itraconazole, in Period 2; a&#xD;
      proton pump inhibitor, rabeprazole, in Period 3; and a strong CYP3A4 inducer, rifampicin, in&#xD;
      Period 4.&#xD;
&#xD;
      Subjects will receive a total of 4 single oral dosses of investigative product (IP), 200 mg&#xD;
      belumosudil QD, in the fed state over 4 periods (each lasting 3 days with a minimum washout&#xD;
      of 2, 8, and 4 days following completion of Periods 1, 2, and 3, respectively). Subjects also&#xD;
      will receive 9 single oral doses of itraconazole 200 mg (QD over 9 days) in Period 2; 7&#xD;
      single oral doses of rabeprazole 20 mg (BID over 3 days followed by QD on 1 day) in Period 3;&#xD;
      and 9 single doses of rifampicin 600 mg (QD over 9 days) in Period 4.&#xD;
&#xD;
      A follow-up visit will take place 3 to 5 days post-final discharge.&#xD;
&#xD;
      Part 2:&#xD;
&#xD;
      The primary objective of Part 2 of this study is to determine the effect of omeprazole on the&#xD;
      PK of a single-day twice daily (BID; every 12 hours [Q12h]) dose of belumosudil administered&#xD;
      orally, in healthy male subjects. Part 2 consists of 2 periods.&#xD;
&#xD;
      In Period 1, subjects will receive a single dose of belumosudil, in the fed state. In Period&#xD;
      2, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of&#xD;
      gastric pH on belumosudil exposure, subjects will receive multiple doses of a proton pump&#xD;
      inhibitor, omeprazole.&#xD;
&#xD;
      Subjects will receive a total of 4 single oral doses of IP (200 mg belumosudil, BID [Q12h] on&#xD;
      2 occasions) in the fed state over 2 periods (each lasting 3 days with a minimum washout of 2&#xD;
      days between dosing in Period 1 and the start of dosing with non-IP in Period 2). Subjects&#xD;
      will also receive 4 single oral doses of omeprazole 20 mg (QD over 4 days) in Period 2.&#xD;
&#xD;
      A follow-up visit will take place 3 to 5 days post-final discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2018</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two-Part, Non-Randomised</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1</measure>
    <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose</time_frame>
    <description>Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax of KD025m1 in Part 1</measure>
    <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose</time_frame>
    <description>Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2</measure>
    <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose</time_frame>
    <description>Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2</measure>
    <time_frame>Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose</time_frame>
    <description>Area under concentration-time curve from zero hours to infinity (AUC[0-inf]) and from zero hours to 24 hours post-dose (AUC[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2</measure>
    <time_frame>Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose</time_frame>
    <description>Area under concentration-time curve from zero hours to 24 hours post-dose (AUC[0-24]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Drug-drug Interaction</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Fibrotic Disease</condition>
  <arm_group>
    <arm_group_label>Part 1, Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.&#xD;
Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.&#xD;
Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.&#xD;
Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.&#xD;
Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belumosudil</intervention_name>
    <description>Development candidate</description>
    <arm_group_label>Part 1, Period 1</arm_group_label>
    <arm_group_label>Part 1, Period 2</arm_group_label>
    <arm_group_label>Part 1, Period 3</arm_group_label>
    <arm_group_label>Part 1, Period 4</arm_group_label>
    <arm_group_label>Part 2, Period 1</arm_group_label>
    <arm_group_label>Part 2, Period 2</arm_group_label>
    <other_name>Rezurock</other_name>
    <other_name>SLx-2119</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Perpetrator drug</description>
    <arm_group_label>Part 1, Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Perpetrator drug</description>
    <arm_group_label>Part 1, Period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Perpetrator drug</description>
    <arm_group_label>Part 1, Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Perpetrator drug</description>
    <arm_group_label>Part 2, Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males&#xD;
&#xD;
          2. Age 18 to 55 years&#xD;
&#xD;
          3. Good state of health (mentally and physically) as indicated by a comprehensive&#xD;
             clinical assessment (detailed medical history and a complete physical examination),&#xD;
             electrocardiogram (ECG) and laboratory investigations (hematology, clinical chemistry,&#xD;
             and urinalysis)&#xD;
&#xD;
          4. Body weight ≥50 kg&#xD;
&#xD;
          5. Body mass index of 18.0 to 32.0 kg/m^2 or, if outside the range, considered not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          6. Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          7. Must provide written informed consent&#xD;
&#xD;
          8. Must adhere to the contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who had previously participated in any other investigational study drug trial&#xD;
             in which receipt of an IP occurred within 90 days prior to dosing. (Subjects who had&#xD;
             previously received belumosudil in Part 1 at least 90 days prior to dosing in Part 2&#xD;
             were eligible to participate.)&#xD;
&#xD;
          2. Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          3. Subjects with pregnant partners&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          5. Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, or a 25&#xD;
             mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)&#xD;
&#xD;
          6. Current smokers and those who have smoked within the last 12 months. A breath carbon&#xD;
             monoxide reading of greater than 10 ppm at screening and admission&#xD;
&#xD;
          7. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator at screening&#xD;
&#xD;
          9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by&#xD;
             the investigator&#xD;
&#xD;
         10. Positive drugs of abuse test result at screening and admission&#xD;
&#xD;
         11. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
         12. Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance (CLcr) of &lt;80 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
         13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, neurological or psychiatric disorder, as judged by the&#xD;
             investigator&#xD;
&#xD;
         14. Subject has a history or presence of any of the following:&#xD;
&#xD;
               -  Active gastrointestinal disease requiring therapy&#xD;
&#xD;
               -  Hepatic disease and/or alanine aminotransaminase (ALT) or aspartate&#xD;
                  aminotransaminase (AST) &gt; ULN&#xD;
&#xD;
               -  Renal disease and/or serum creatinine &gt; ULN&#xD;
&#xD;
               -  Other condition known to interfere with the absorption, distribution, metabolism&#xD;
                  or excretion of drugs&#xD;
&#xD;
         15. Subjects with a history of cholecystectomy or gall stones&#xD;
&#xD;
         16. Subject has QT interval corrected using Fridericia's formula (QTcF) intervals &gt;450&#xD;
             msec at screening or admission&#xD;
&#xD;
         17. Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients; including intolerance to itraconazole, rabeprazole, and rifampicin&#xD;
&#xD;
         18. Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hayfever is allowed unless it is active&#xD;
&#xD;
         19. Donation or loss of greater than 400 mL of blood within the previous 3 months&#xD;
&#xD;
         20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than 4 g per day paracetamol) or herbal remedies in the 14 days before IP&#xD;
             administration.&#xD;
&#xD;
         21. Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
&#xD;
        Subjects Agreed to the Following Restrictions During the Duration of the Study:&#xD;
&#xD;
          1. No alcohol during the 24-hour period prior to screening and the 24-hour period prior&#xD;
             to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1,&#xD;
             Periods 2 to 4 and Part 2, Period 2, until discharge for each treatment period.&#xD;
&#xD;
          2. No food or drinks containing grapefruit or cranberry from 24 hours prior to admission&#xD;
             in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1 Periods 2 to&#xD;
             4 and Part 2 Period 2, until discharge for each treatment period.&#xD;
&#xD;
          3. No food or drinks containing caffeine or other xanthines from 24 hours prior to&#xD;
             admission until discharge for each treatment period.&#xD;
&#xD;
          4. No food containing poppy seeds for 48 hours prior to screening and for 24 hours prior&#xD;
             to admission until discharge for each treatment period.&#xD;
&#xD;
          5. No unaccustomed or strenuous exercise from the 72-hour period before the screening&#xD;
             visit and then from 24 hours prior to admission until discharge for each treatment&#xD;
             period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences Ltd</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03530995/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03530995/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single centre, non-randomised, open label, two-part study. Part 1 of the study was a 4-period sequential dose study in healthy male subjects. The estimated duration from screening to discharge from the study was approximately 10 weeks. Part 2 of the study was a 2-period sequential dose study in healthy males. The estimated duration from screening to discharge from the study was approximately 7 weeks.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Belumosudil (KD025) QD Dosing</title>
          <description>Subjects received a single dose of belumosudil 200 mg on 4 separate occasions, and multiple single doses of itraconazole, rabeprazole and rifampicin, on separate occasions, for 9,4 and 9 consecutive days, respectively.</description>
        </group>
        <group group_id="P2">
          <title>Part 2 Belumosudil (KD025) BID Dosing</title>
          <description>Subjects received a twice daily dose of belumosudil 200 mg on 2 separate occasions, and single doses of omeprazole for 4 consecutive days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 Period 1; Part 2 Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1 Period 2; Part 2 Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1 Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="0">Period 3 is not applicable to part 2 of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="0">Period 3 is not applicable to part 2 of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1 Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="0">Period 4 is not applicable to part 2 of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0">Period 4 is not applicable to part 2 of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects Part 1: KD025 QD Dosing</title>
          <description>Period 1: 200 mg KD025 QD alone; Period 2: 200 mg KD025 QD with Itraconazole; Period 3: 200 mg KD025 QD with Rabeprazole; Period 4: 200 mg KD025 QD with Rifampicin</description>
        </group>
        <group group_id="B2">
          <title>All Subjects in Part 2: KD025 BID Dosing</title>
          <description>Period 1: 200 mg KD025 BID alone; Period 2: 200 mg KD025 BID with Omeprazole</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="11.8"/>
                    <measurement group_id="B2" value="32.6" spread="10.6"/>
                    <measurement group_id="B3" value="34.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (body mass index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.81" spread="3.00"/>
                    <measurement group_id="B2" value="25.94" spread="3.36"/>
                    <measurement group_id="B3" value="26.36" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1</title>
        <description>Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose</description>
        <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose</time_frame>
        <population>Subject in Part 1 who received belumosudil alone, belumosudil with itraconazole, belumosudil with rabeprazole, and belumosudil with rifampicin. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg single dose on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 2: Belumosudil + Itraconazole</title>
            <description>Itraconazole 200 mg QD on Day 1 through Day 7; Belumosudil 200 mg + Itraconazole 200 mg QD on Day 8; Itraconazole 200 mg QD on Day 9</description>
          </group>
          <group group_id="O3">
            <title>Part 1, Period 3: Belumosudil + Rabeprazole</title>
            <description>Rabeprazole 20 mg BID on Day 1 through Day 3; Belumosudil 200 mg + Rabeprazole 20 mg QD on Day 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1, Period 4: Belumosudil + Rifampicin</title>
            <description>Rifampicin 600 mg QD on Day 1-9; Belumosudil 200 mg on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1</title>
          <description>Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose</description>
          <population>Subject in Part 1 who received belumosudil alone, belumosudil with itraconazole, belumosudil with rabeprazole, and belumosudil with rifampicin. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parent Drug KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1770" spread="31.3"/>
                    <measurement group_id="O2" value="2130" spread="31.0"/>
                    <measurement group_id="O3" value="227" spread="58.4"/>
                    <measurement group_id="O4" value="712" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337" spread="54.7"/>
                    <measurement group_id="O2" value="221" spread="60.8"/>
                    <measurement group_id="O3" value="23.5" spread="70.7"/>
                    <measurement group_id="O4" value="148" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Cmax of KD025m1 in Part 1</title>
        <description>Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose</description>
        <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose</time_frame>
        <population>Subjects in Part 1 who received belumosudil alone and belumosudil with rifampicin. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg single dose on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 4: Belumosudil + Rifampicin</title>
            <description>Rifampicin 600 mg QD on Day 1-9; Belumosudil 200 mg on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax of KD025m1 in Part 1</title>
          <description>Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose</description>
          <population>Subjects in Part 1 who received belumosudil alone and belumosudil with rifampicin. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="40.0"/>
                    <measurement group_id="O2" value="52.5" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2</title>
        <description>Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose</description>
        <time_frame>Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose</time_frame>
        <population>Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg BID (Q12h) on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: Belumosudil + Omeprazole</title>
            <description>Omeprazole 20 mg QD fasted for 3 days (Period 2 Days -3 to -1), Omeprazole 20 mg QD fasted + Belumosudil 200 mg BID (Q12h) fed on 4th day (Period 2 Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2</title>
          <description>Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose</description>
          <population>Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax--1st dose: KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1790" spread="34.5"/>
                    <measurement group_id="O2" value="575" spread="145.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax--2nd dose: KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1760" spread="37.0"/>
                    <measurement group_id="O2" value="903" spread="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax--1st Dose: KD025m1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="39.6"/>
                    <measurement group_id="O2" value="18.0" spread="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax--2nd Dose: KD025m1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="46.4"/>
                    <measurement group_id="O2" value="18.9" spread="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax--1st Dose: KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="75.6"/>
                    <measurement group_id="O2" value="72.3" spread="166.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax--2nd Dose: KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257" spread="83.9"/>
                    <measurement group_id="O2" value="115" spread="121.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2</title>
        <description>Area under concentration-time curve from zero hours to infinity (AUC[0-inf]) and from zero hours to 24 hours post-dose (AUC[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2</description>
        <time_frame>Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose</time_frame>
        <population>Subjects in Part 1 who received belumosudil alone, belumosudil with itraconazole, belumosudil with rabeprazole, and belumosudil with rifampicin; Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg single dose on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 2: Belumosudil + Itraconazole</title>
            <description>Itraconazole 200 mg QD on Day 1-7; Belumosudil 200 mg + Itraconazole 200 mg QD on Day 8; Itraconazole 200 mg QD on Day 9</description>
          </group>
          <group group_id="O3">
            <title>Part 1, Period 3: Belumosudil + Rabeprazole</title>
            <description>Rabeprazole 20 mg BID on Day 1-3; Belumosudil 200 mg + Rabeprazole 20 mg QD on Day 4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1, Period 4: Belumosudil + Rifampicin</title>
            <description>Rifampicin 600 mg QD on Day 1-9; Belumosudil 200 mg on Day 10</description>
          </group>
          <group group_id="O5">
            <title>Part 2, Period 1: Belumosudil Only</title>
            <description>Belumosudil 200 mg BID (Q12h) fed on a single day, Period 1 Day 1</description>
          </group>
          <group group_id="O6">
            <title>Part 2, Period 2: Belumosudil + Omeprazole</title>
            <description>Omeprazole 20 mg QD fasted for 3 days (Period 2, Days -3 to -1); Omeprazole 20 mg QD fasted + Belumosudil 200 mg BID (Q12h) fed on 4th day (Period 2 Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2</title>
          <description>Area under concentration-time curve from zero hours to infinity (AUC[0-inf]) and from zero hours to 24 hours post-dose (AUC[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2</description>
          <population>Subjects in Part 1 who received belumosudil alone, belumosudil with itraconazole, belumosudil with rabeprazole, and belumosudil with rifampicin; Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
          <units>(ng*h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-inf): KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9080" spread="33.3"/>
                    <measurement group_id="O2" value="11200" spread="38.1"/>
                    <measurement group_id="O3" value="1680" spread="65.8"/>
                    <measurement group_id="O4" value="2500" spread="34.5"/>
                    <measurement group_id="O5" value="18800" spread="37.1"/>
                    <measurement group_id="O6" value="9880" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-inf): KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230" spread="69.5"/>
                    <measurement group_id="O2" value="843" spread="73.7"/>
                    <measurement group_id="O3" value="174" spread="11.1"/>
                    <measurement group_id="O4" value="396" spread="50.2"/>
                    <measurement group_id="O5" value="1900" spread="90.4"/>
                    <measurement group_id="O6" value="1110" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24): KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8430" spread="30.5"/>
                    <measurement group_id="O2" value="10400" spread="35.8"/>
                    <measurement group_id="O3" value="1510" spread="60.7"/>
                    <measurement group_id="O4" value="2490" spread="34.1"/>
                    <measurement group_id="O5" value="16800" spread="36.4"/>
                    <measurement group_id="O6" value="7970" spread="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24): KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="63.7"/>
                    <measurement group_id="O2" value="745" spread="70.7"/>
                    <measurement group_id="O3" value="110" spread="84.0"/>
                    <measurement group_id="O4" value="376" spread="56.7"/>
                    <measurement group_id="O5" value="1950" spread="82.3"/>
                    <measurement group_id="O6" value="767" spread="115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2</title>
        <description>Area under concentration-time curve from zero hours to 24 hours post-dose (AUC[0-24]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2</description>
        <time_frame>Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose</time_frame>
        <population>Subjects in Part 1 who received belumosudil alone and belumosudil with rifampicin; Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg single dose on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 4: Belumosudil + Rifampicin</title>
            <description>Rifampicin 600 mg QD on Day 1-9; Belumosudil 200 mg on Day 10.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Period 1: Belumosudil Alone</title>
            <description>Belumosudil 200 mg BID (Q12h) fed on a single day, Period 1 Day 1</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Period 2: Belumosudil + Omeprazole</title>
            <description>Omeprazole 20 mg QD fasted for 3 days (Period 2, Days -3 to -1); Omeprazole 20 mg QD fasted + Belumosudil 200 mg BID (Q12h) fed on 4th day (Period 2 Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2</title>
          <description>Area under concentration-time curve from zero hours to 24 hours post-dose (AUC[0-24]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2</description>
          <population>Subjects in Part 1 who received belumosudil alone and belumosudil with rifampicin; Subjects in Part 2 who received belumosudil alone and belumosudil with omeprazole. The number of subjects who participated in the study may differ from the number of subjects with an observation due to missing samples at critical timepoints or protocol deviations.</population>
          <units>(ng*h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="42.1"/>
                    <measurement group_id="O2" value="148" spread="41.9"/>
                    <measurement group_id="O3" value="138" spread="91.3"/>
                    <measurement group_id="O4" value="91.5" spread="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1, Period 1: 1 day Part 1, Period 2: 9 days Part 1, Period 3: 4 days Part 1, Period 4: 10 days Part 2, Period 1: 1 day Part 2, Period 2: 4 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1, Period 1: Belumosudil Only</title>
          <description>Belumosudil 200 mg single dose on Day 1</description>
        </group>
        <group group_id="E2">
          <title>Part 1, Period 2: Belumosudil + Itraconazole</title>
          <description>Itraconazole 200 mg QD Day 1-7, Belumosudil 200 mg QD with itraconazole on Day 8, Itraconazole 200 mg QD on Day 9</description>
        </group>
        <group group_id="E3">
          <title>Part 1, Period 3: Belumosudil +Rabeprazole</title>
          <description>Rabeprazole 20 mg BID on Day 1-3, Belumosudil 200 mg + rabeprazole 20 mg QD on Day 4</description>
        </group>
        <group group_id="E4">
          <title>Part 1, Period 4: Belumosudil + Rifampicin</title>
          <description>Rifampicin 600 mg QD on Day 1-9, Belumosudil 200 mg on Day 10</description>
        </group>
        <group group_id="E5">
          <title>Part 2, Period 1: Belumosudil Only</title>
          <description>Belumosudil 200 mg BID (Q12h) fed on a single day, Period 1 Day 1: KD025 200 mg BID</description>
        </group>
        <group group_id="E6">
          <title>Part 2, Period 2: Belumosudil + Omeprazole</title>
          <description>Omeprazole 20 mg QD fasted for 3 days (Period 2 Days -3 to -10, Omeprazole 20 mg QD fasted + Belumosudil 200 mg BID (Q12h) fed on 4th day (Period 2 Day 1)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Medical device site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olivier Schueller, Senior Vice President, CMC &amp; Clinical Pharmacology</name_or_title>
      <organization>Kadmon Corporation</organization>
      <phone>833-900-5366</phone>
      <email>olivier.schueller@kadmon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

